Balyasny Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-65,156
Closed -$220K 3196
2025
Q4
$220K Buy
+65,156
New +$169K ﹤0.01% 2851
2025
Q3
Sell
-17,743
Closed -$12.7K 3178
2025
Q2
$12.7K Sell
17,743
-292,517
-94% -$230K ﹤0.01% 2724
2025
Q1
$456K Buy
+310,260
New +$739K ﹤0.01% 2303
2024
Q1
Sell
-21,660
Closed -$263K 2858
2023
Q4
$248K Sell
21,660
-8,248
-28% -$81.6K ﹤0.01% 2241
2023
Q3
$288K Sell
29,908
-1,658,105
-98% -$16.3M ﹤0.01% 1928
2023
Q2
$18M Buy
1,688,013
+737,277
+78% +$7.92M 0.04% 568
2023
Q1
$10M Buy
+950,736
New +$10.7M 0.03% 779
2022
Q3
Sell
-118,980
Closed -$1.37M 3037
2022
Q2
$1.37M Buy
+118,980
New +$1.4M ﹤0.01% 1622
2020
Q3
Sell
-31,670
Closed -$327K 1436
2020
Q2
$327K Buy
31,670
+18,883
+148% +$193K ﹤0.01% 982
2020
Q1
$129K Buy
+12,787
New +$150K ﹤0.01% 1075
2019
Q3
Sell
-20,747
Closed -$227K 1368
2019
Q2
$227K Buy
20,747
+5,313
+34% +$59.5K ﹤0.01% 1383
2019
Q1
$175K Sell
15,434
-19,439
-56% -$217K ﹤0.01% 1356
2018
Q4
$303K Buy
+34,873
New +$400K ﹤0.01% 1227
2018
Q3
Sell
-20,790
Closed -$333K 1846
2018
Q2
$333K Buy
20,790
+4,466
+27% +$66.1K ﹤0.01% 1480
2018
Q1
$211K Buy
+16,324
New +$203K ﹤0.01% 1742

Other funds holding IRWD

Balyasny Asset Management's IRWD Position: Q1 2026 in Review

Balyasny Asset Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2026, closing a stake of 65,156 shares — an estimated $220K sold.

Balyasny Asset Management first reported a position in IRWD in Q1 2018 and held it in 15 quarters. The position peaked at $18M in Q2 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Balyasny Asset Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 65,156 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $220K.
  • Balyasny Asset Management first reported a position in Ironwood Pharmaceuticals in Q1 2018 and held it in 15 quarters.
  • Balyasny Asset Management's Ironwood Pharmaceuticals position peaked at $18M in Q2 2023.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.